NYSE · CIK 0000014272
BMY BRISTOL MYERS SQUIBB CO
Insider trading from SEC Form 4. Last filing 6 d ago. Close $59.12 on Oct 9, 2026, +45% from the 52-week low and -12% from the high.
Last 90 days
Net insider value
-$403k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$403k by 1 insider
Insiders on file
20
with a Form 4 at this company
Price and insider trades, last year
BMYOct 9, 2026 · close 59.12
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BRISTOL MYERS SQUIBB CO, scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 36Weak | sell | Cristian Massacesi EVP,Chief Med Offr,Head of Dev | $403k | 6,249 | -25% | - | |
| 43Moderate | buy 2 | Christopher S. Boerner Chief Executive Officer | $110k | 2,000 | +2% | - | |
| 33Weak | buy 2 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | $100k | 1,823 | +3% | - | |
| 25Weak | buy | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | $100k | 1,830 | +3% | - | |
| 21Weak | sell | Phil M Holzer SVP and Controller | $39k | 700 | -6% | - |
Congressional trades
19 trades in BMY disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Tommy Tuberville Senate · R-AL | Sale | BMY Bristol-Myers Squibb Company | $1,001 to $15k | Apr 15, 2025 | 477 days after the trade |
| Alan Armstrong Senate · R-OK | Purchase | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Mar 27, 2026 | 116 days after the trade |
| Mike Kelly House · R-PA | Sale | BMY Bristol-Myers Squibb Company Common Stock | $15k to $50k | May 7, 2026 | 35 days after the trade |
| Julie Johnson House · D-TX | Sale | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Dec 18, 2025 | 28 days after the trade |
| Julia Letlow House · R-LA | Purchase | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Oct 23, 2024 | 447 days after the trade |
| Julia Letlow House · R-LA | Sale | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Apr 28, 2025 | 260 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Dec 19, 2025 | 24 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Nov 12, 2025 | 33 days after the trade |
| Julie Johnson House · D-TX | Partial sale | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Nov 13, 2025 | 28 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Partial sale | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Oct 9, 2025 | 40 days after the trade |
| Val T. Hoyle House · D-OR | Purchase | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Oct 29, 2024 | 318 days after the trade |
| Julie Johnson House · D-TX | Partial sale | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Aug 14, 2025 | 28 days after the trade |
| Virginia Foxx House · R-NC | Sale | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Jun 24, 2025 | 9 days after the trade |
| Jefferson Shreve House · R-IN | Sale | BMY Bristol-Myers Squibb Company Common Stock | $15k to $50k | May 12, 2025 | 41 days after the trade |
| Tommy Tuberville Senate · R-AL | Sale | BMY Bristol-Myers Squibb Company | $1,001 to $15k | Apr 15, 2025 | 30 days after the trade |
| Julie Johnson House · D-TX | Sale | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Apr 1, 2025 | 43 days after the trade |
| Greg Landsman House · D-OH | Sale | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Mar 27, 2025 | 12 days after the trade |
| Julie Johnson House · D-TX | Purchase | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Jan 15, 2025 | 28 days after the trade |
| Virginia Foxx House · R-NC | Purchase | BMY Bristol-Myers Squibb Company Common Stock | $1,001 to $15k | Dec 6, 2024 | 31 days after the trade |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Cari Gallman EVP, General Counsel | MOption exercise Common Stock, $0.10 par value | +4,559 | $0.00 | $0 | 18,208 | 6 d ago |
| Oct 2, 2026 | Cari Gallman EVP, General Counsel | FTax withholding Common Stock, $0.10 par value | -2,332 | $61.15 | $143k | 15,876 | 6 d ago |
| Oct 2, 2026 | Cari Gallman EVP, General Counsel | MOption exercise Restricted Stock Unitsderivative | -4,559 | $0.00 | $0 | 0 | 6 d ago |
| Sep 30, 2026 | Phyllis R Yale director | AGrant or award Deferred Share Unitsderivative | +561 | $62.40 | $35k | 45,980 | 9 d ago |
| Sep 30, 2026 | Theodore R. Samuels II director | AGrant or award Deferred Share Unitsderivative | +821 | $62.40 | $51k | 71,859 | 9 d ago |
| Sep 30, 2026 | Peter J Arduini director | AGrant or award Deferred Share Unitsderivative | +561 | $62.40 | $35k | 74,077 | 9 d ago |
| Sep 30, 2026 | Derica W Rice director | AGrant or award Deferred Share Unitsderivative | +621 | $62.40 | $39k | 42,085 | 9 d ago |
| Sep 30, 2026 | Michael R. McMullen director | AGrant or award Deferred Share Unitsderivative | +561 | $62.40 | $35k | 17,051 | 9 d ago |
| Sep 9, 2026 | Cristian Massacesi EVP,Chief Med Offr,Head of Dev | SOpen-market sale Common Stock, $0.10 par value | -6,249 | $64.57 | $403k | 18,748 | 31 d ago |
| Sep 1, 2026 | Bartie Wendy Short EVP, Corporate Affairs | MOption exercise Common Stock, $0.10 par value | +1,236 | $66.92 | $83k | 13,317 | 38 d ago |
| Sep 1, 2026 | Bartie Wendy Short EVP, Corporate Affairs | FTax withholding Common Stock, $0.10 par value | -633 | $66.92 | $42k | 12,684 | 38 d ago |
| Sep 1, 2026 | Bartie Wendy Short EVP, Corporate Affairs | MOption exercise Restricted Stock Unitsderivative | -1,236 | $0.00 | $0 | 0 | 38 d ago |
| Mar 10, 2025 | Adam Lenkowsky EVP, Chief Commercial Officer | MOption exercise Common Stock, $0.10 par value | +1,904 | $0.00 | $0 | 8,554 | Mar 12, 2025 |
| Mar 10, 2025 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | MOption exercise Common Stock, $0.10 par value | +4,886 | $0.00 | $0 | 68,818 | Mar 12, 2025 |
| Mar 10, 2025 | Lynelle Hoch President, Cell Therapy Org. | MOption exercise Common Stock, $0.10 par value | +546 | $0.00 | $0 | 2,272 | Mar 12, 2025 |
| Mar 10, 2025 | Sandra Leung EVP, General Counsel | MOption exercise Common Stock, $0.10 par value | +5,858 | $0.00 | $0 | 353,243 | Mar 12, 2025 |
| Mar 10, 2025 | Karin Shanahan EVP, Glob. Prod. Dev. & Supply | MOption exercise Common Stock, $0.10 par value | +2,447 | $0.00 | $0 | 7,783 | Mar 12, 2025 |
| Mar 10, 2025 | Gregory Scott Meyers EVP, Chief Digital & Tech Off. | MOption exercise Common Stock, $0.10 par value | +2,836 | $0.00 | $0 | 9,832 | Mar 12, 2025 |
| Mar 10, 2025 | Ahn Amanda Poole EVP, Chief People Officer | MOption exercise Common Stock, $0.10 par value | +690 | $0.00 | $0 | 3,114 | Mar 12, 2025 |
| Mar 10, 2025 | Robert M Plenge EVP, Chief Research Officer | MOption exercise Common Stock, $0.10 par value | +1,165 | $0.00 | $0 | 12,480 | Mar 12, 2025 |
| Mar 10, 2025 | Christopher S. Boerner Chief Executive Officer | MOption exercise Common Stock, $0.10 par value | +6,985 | $0.00 | $0 | 111,611 | Mar 12, 2025 |
| Mar 10, 2025 | Phil M Holzer SVP and Controller | MOption exercise Common Stock, $0.10 par value | +701 | $0.00 | $0 | 12,461 | Mar 12, 2025 |
| Mar 10, 2025 | Cari Gallman EVP, Corporate Affairs | MOption exercise Common Stock, $0.10 par value | +349 | $0.00 | $0 | 5,368 | Mar 12, 2025 |
| Mar 10, 2025 | David Elkins V EVP, Chief Financial Officer | MOption exercise Common Stock, $0.10 par value | +8,045 | $0.00 | $0 | 203,013 | Mar 12, 2025 |
| Mar 10, 2025 | David Elkins V EVP, Chief Financial Officer | JOther Common Stock, $0.10 par value | -555 | $0.00 | $0 | 202,458 | Mar 12, 2025 |
| Mar 10, 2025 | Lynelle Hoch President, Cell Therapy Org. | JOther Common Stock, $0.10 par value | -38 | $0.00 | $0 | 2,234 | Mar 12, 2025 |
| Mar 10, 2025 | Karin Shanahan EVP, Glob. Prod. Dev. & Supply | JOther Common Stock, $0.10 par value | -427 | $0.00 | $0 | 7,356 | Mar 12, 2025 |
| Mar 10, 2025 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | JOther Common Stock, $0.10 par value | -337 | $0.00 | $0 | 68,481 | Mar 12, 2025 |
| Mar 10, 2025 | Phil M Holzer SVP and Controller | JOther Common Stock, $0.10 par value | -48 | $0.00 | $0 | 12,413 | Mar 12, 2025 |
| Mar 10, 2025 | Ahn Amanda Poole EVP, Chief People Officer | JOther Common Stock, $0.10 par value | -48 | $0.00 | $0 | 3,066 | Mar 12, 2025 |
| Mar 10, 2025 | Robert M Plenge EVP, Chief Research Officer | JOther Common Stock, $0.10 par value | -80 | $0.00 | $0 | 12,400 | Mar 12, 2025 |
| Mar 10, 2025 | Gregory Scott Meyers EVP, Chief Digital & Tech Off. | JOther Common Stock, $0.10 par value | -495 | $0.00 | $0 | 9,337 | Mar 12, 2025 |
| Mar 10, 2025 | Cari Gallman EVP, Corporate Affairs | JOther Common Stock, $0.10 par value | -24 | $0.00 | $0 | 5,344 | Mar 12, 2025 |
| Mar 10, 2025 | Adam Lenkowsky EVP, Chief Commercial Officer | JOther Common Stock, $0.10 par value | -131 | $0.00 | $0 | 8,423 | Mar 12, 2025 |
| Mar 10, 2025 | Sandra Leung EVP, General Counsel | JOther Common Stock, $0.10 par value | -404 | $0.00 | $0 | 352,839 | Mar 12, 2025 |
| Mar 10, 2025 | Christopher S. Boerner Chief Executive Officer | JOther Common Stock, $0.10 par value | -482 | $0.00 | $0 | 111,129 | Mar 12, 2025 |
| Mar 10, 2025 | Benjamin Hickey President, RayzeBio Org. | AGrant or award Market Share Unitsderivative | +13,389 | $0.00 | $0 | 13,389 | Mar 12, 2025 |
| Mar 10, 2025 | David Elkins V EVP, Chief Financial Officer | FTax withholding Common Stock, $0.10 par value | -3,178 | $63.11 | $201k | 199,280 | Mar 12, 2025 |
| Mar 10, 2025 | Lynelle Hoch President, Cell Therapy Org. | FTax withholding Common Stock, $0.10 par value | -219 | $63.11 | $14k | 2,015 | Mar 12, 2025 |
| Mar 10, 2025 | Gregory Scott Meyers EVP, Chief Digital & Tech Off. | FTax withholding Common Stock, $0.10 par value | -994 | $63.11 | $63k | 8,343 | Mar 12, 2025 |
| Mar 10, 2025 | Adam Lenkowsky EVP, Chief Commercial Officer | FTax withholding Common Stock, $0.10 par value | -907 | $63.11 | $57k | 7,516 | Mar 12, 2025 |
| Mar 10, 2025 | Cari Gallman EVP, Corporate Affairs | FTax withholding Common Stock, $0.10 par value | -118 | $63.11 | $7,447 | 5,226 | Mar 12, 2025 |
| Mar 10, 2025 | Karin Shanahan EVP, Glob. Prod. Dev. & Supply | FTax withholding Common Stock, $0.10 par value | -1,034 | $63.11 | $65k | 6,322 | Mar 12, 2025 |
| Mar 10, 2025 | Phil M Holzer SVP and Controller | FTax withholding Common Stock, $0.10 par value | -237 | $63.11 | $15k | 12,176 | Mar 12, 2025 |
| Mar 10, 2025 | Ahn Amanda Poole EVP, Chief People Officer | FTax withholding Common Stock, $0.10 par value | -233 | $63.11 | $15k | 2,833 | Mar 12, 2025 |
| Mar 10, 2025 | Robert M Plenge EVP, Chief Research Officer | FTax withholding Common Stock, $0.10 par value | -482 | $63.11 | $30k | 11,918 | Mar 12, 2025 |
| Mar 10, 2025 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | FTax withholding Common Stock, $0.10 par value | -2,327 | $63.11 | $147k | 66,154 | Mar 12, 2025 |
| Mar 10, 2025 | Sandra Leung EVP, General Counsel | FTax withholding Common Stock, $0.10 par value | -2,790 | $63.11 | $176k | 350,049 | Mar 12, 2025 |
| Mar 10, 2025 | Christopher S. Boerner Chief Executive Officer | FTax withholding Common Stock, $0.10 par value | -3,327 | $63.11 | $210k | 107,802 | Mar 12, 2025 |
| Mar 10, 2025 | Christopher S. Boerner Chief Executive Officer | MOption exercise Common Stock, $0.10 par value | +6,616 | $0.00 | $0 | 114,418 | Mar 12, 2025 |
| Mar 10, 2025 | Benjamin Hickey President, RayzeBio Org. | AGrant or award Performance Sharesderivative | +20,084 | $0.00 | $0 | 20,084 | Mar 12, 2025 |
| Mar 10, 2025 | Ahn Amanda Poole EVP, Chief People Officer | MOption exercise Common Stock, $0.10 par value | +810 | $0.00 | $0 | 3,643 | Mar 12, 2025 |
| Mar 10, 2025 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | MOption exercise Common Stock, $0.10 par value | +4,765 | $0.00 | $0 | 70,919 | Mar 12, 2025 |
| Mar 10, 2025 | David Elkins V EVP, Chief Financial Officer | MOption exercise Common Stock, $0.10 par value | +7,652 | $0.00 | $0 | 206,932 | Mar 12, 2025 |
| Mar 10, 2025 | Robert M Plenge EVP, Chief Research Officer | MOption exercise Common Stock, $0.10 par value | +1,107 | $0.00 | $0 | 13,025 | Mar 12, 2025 |
| Mar 10, 2025 | Gregory Scott Meyers EVP, Chief Digital & Tech Off. | MOption exercise Common Stock, $0.10 par value | +3,293 | $0.00 | $0 | 11,636 | Mar 12, 2025 |
| Mar 10, 2025 | Lynelle Hoch President, Cell Therapy Org. | MOption exercise Common Stock, $0.10 par value | +835 | $0.00 | $0 | 2,850 | Mar 12, 2025 |
| Mar 10, 2025 | Sandra Leung EVP, General Counsel | MOption exercise Common Stock, $0.10 par value | +5,349 | $0.00 | $0 | 355,398 | Mar 12, 2025 |
| Mar 10, 2025 | Phil M Holzer SVP and Controller | MOption exercise Common Stock, $0.10 par value | +810 | $0.00 | $0 | 12,986 | Mar 12, 2025 |
| Mar 10, 2025 | Cari Gallman EVP, Corporate Affairs | MOption exercise Common Stock, $0.10 par value | +910 | $0.00 | $0 | 6,136 | Mar 12, 2025 |
| Mar 10, 2025 | Karin Shanahan EVP, Glob. Prod. Dev. & Supply | MOption exercise Common Stock, $0.10 par value | +3,293 | $0.00 | $0 | 9,615 | Mar 12, 2025 |
| Mar 10, 2025 | Adam Lenkowsky EVP, Chief Commercial Officer | MOption exercise Common Stock, $0.10 par value | +1,825 | $0.00 | $0 | 9,341 | Mar 12, 2025 |
| Mar 10, 2025 | Christopher S. Boerner Chief Executive Officer | JOther Common Stock, $0.10 par value | -1,154 | $0.00 | $0 | 113,264 | Mar 12, 2025 |
| Mar 10, 2025 | David Elkins V EVP, Chief Financial Officer | JOther Common Stock, $0.10 par value | -1,335 | $0.00 | $0 | 205,597 | Mar 12, 2025 |
| Mar 10, 2025 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | JOther Common Stock, $0.10 par value | -831 | $0.00 | $0 | 70,088 | Mar 12, 2025 |
| Mar 10, 2025 | Robert M Plenge EVP, Chief Research Officer | JOther Common Stock, $0.10 par value | -193 | $0.00 | $0 | 12,832 | Mar 12, 2025 |
| Mar 10, 2025 | Ahn Amanda Poole EVP, Chief People Officer | JOther Common Stock, $0.10 par value | -141 | $0.00 | $0 | 3,502 | Mar 12, 2025 |
| Mar 10, 2025 | Sandra Leung EVP, General Counsel | JOther Common Stock, $0.10 par value | -933 | $0.00 | $0 | 354,465 | Mar 12, 2025 |
| Mar 10, 2025 | Phil M Holzer SVP and Controller | JOther Common Stock, $0.10 par value | -141 | $0.00 | $0 | 12,845 | Mar 12, 2025 |
| Mar 10, 2025 | Adam Lenkowsky EVP, Chief Commercial Officer | JOther Common Stock, $0.10 par value | -318 | $0.00 | $0 | 9,023 | Mar 12, 2025 |
| Mar 10, 2025 | Cari Gallman EVP, Corporate Affairs | JOther Common Stock, $0.10 par value | -159 | $0.00 | $0 | 5,977 | Mar 12, 2025 |
| Mar 10, 2025 | Karin Shanahan EVP, Glob. Prod. Dev. & Supply | JOther Common Stock, $0.10 par value | -561 | $0.00 | $0 | 9,054 | Mar 12, 2025 |
| Mar 10, 2025 | Gregory Scott Meyers EVP, Chief Digital & Tech Off. | JOther Common Stock, $0.10 par value | -561 | $0.00 | $0 | 11,075 | Mar 12, 2025 |
| Mar 10, 2025 | Lynelle Hoch President, Cell Therapy Org. | JOther Common Stock, $0.10 par value | -146 | $0.00 | $0 | 2,704 | Mar 12, 2025 |
| Mar 10, 2025 | David Elkins V EVP, Chief Financial Officer | FTax withholding Common Stock, $0.10 par value | -2,680 | $63.11 | $169k | 202,917 | Mar 12, 2025 |
| Mar 10, 2025 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | FTax withholding Common Stock, $0.10 par value | -2,013 | $63.11 | $127k | 68,075 | Mar 12, 2025 |
| Mar 10, 2025 | Christopher S. Boerner Chief Executive Officer | FTax withholding Common Stock, $0.10 par value | -2,794 | $63.11 | $176k | 110,470 | Mar 12, 2025 |
| Mar 10, 2025 | Robert M Plenge EVP, Chief Research Officer | FTax withholding Common Stock, $0.10 par value | -406 | $63.11 | $26k | 12,426 | Mar 12, 2025 |
| Mar 10, 2025 | Phil M Holzer SVP and Controller | FTax withholding Common Stock, $0.10 par value | -242 | $63.11 | $15k | 12,603 | Mar 12, 2025 |
| Mar 10, 2025 | Karin Shanahan EVP, Glob. Prod. Dev. & Supply | FTax withholding Common Stock, $0.10 par value | -1,398 | $63.11 | $88k | 7,656 | Mar 12, 2025 |
| Mar 10, 2025 | Lynelle Hoch President, Cell Therapy Org. | FTax withholding Common Stock, $0.10 par value | -296 | $63.11 | $19k | 2,408 | Mar 12, 2025 |
| Mar 10, 2025 | Sandra Leung EVP, General Counsel | FTax withholding Common Stock, $0.10 par value | -2,259 | $63.11 | $143k | 352,206 | Mar 12, 2025 |
| Mar 10, 2025 | Gregory Scott Meyers EVP, Chief Digital & Tech Off. | FTax withholding Common Stock, $0.10 par value | -1,159 | $63.11 | $73k | 9,916 | Mar 12, 2025 |
| Mar 10, 2025 | Cari Gallman EVP, Corporate Affairs | FTax withholding Common Stock, $0.10 par value | -272 | $63.11 | $17k | 5,705 | Mar 12, 2025 |
| Mar 10, 2025 | Ahn Amanda Poole EVP, Chief People Officer | FTax withholding Common Stock, $0.10 par value | -242 | $63.11 | $15k | 3,260 | Mar 12, 2025 |
| Mar 10, 2025 | Adam Lenkowsky EVP, Chief Commercial Officer | FTax withholding Common Stock, $0.10 par value | -771 | $63.11 | $49k | 8,252 | Mar 12, 2025 |
| Mar 10, 2025 | Lynelle Hoch President, Cell Therapy Org. | MOption exercise Common Stock, $0.10 par value | +1,050 | $0.00 | $0 | 3,458 | Mar 12, 2025 |
| Mar 10, 2025 | David Elkins V EVP, Chief Financial Officer | MOption exercise Common Stock, $0.10 par value | +7,904 | $0.00 | $0 | 210,821 | Mar 12, 2025 |
| Mar 10, 2025 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | MOption exercise Common Stock, $0.10 par value | +5,854 | $0.00 | $0 | 73,929 | Mar 12, 2025 |
| Mar 10, 2025 | Christopher S. Boerner Chief Executive Officer | MOption exercise Common Stock, $0.10 par value | +6,733 | $0.00 | $0 | 117,203 | Mar 12, 2025 |
| Mar 10, 2025 | Adam Lenkowsky EVP, Chief Commercial Officer | MOption exercise Common Stock, $0.10 par value | +2,000 | $0.00 | $0 | 10,252 | Mar 12, 2025 |
| Mar 10, 2025 | Phil M Holzer SVP and Controller | MOption exercise Common Stock, $0.10 par value | +768 | $0.00 | $0 | 13,371 | Mar 12, 2025 |
| Mar 10, 2025 | Sandra Leung EVP, General Counsel | MOption exercise Common Stock, $0.10 par value | +5,415 | $0.00 | $0 | 357,621 | Mar 12, 2025 |
| Mar 10, 2025 | Ahn Amanda Poole EVP, Chief People Officer | MOption exercise Common Stock, $0.10 par value | +803 | $0.00 | $0 | 4,063 | Mar 12, 2025 |
| Mar 10, 2025 | Robert M Plenge EVP, Chief Research Officer | MOption exercise Common Stock, $0.10 par value | +2,342 | $0.00 | $0 | 14,768 | Mar 12, 2025 |
| Mar 10, 2025 | Gregory Scott Meyers EVP, Chief Digital & Tech Off. | MOption exercise Common Stock, $0.10 par value | +17,021 | $0.00 | $0 | 26,937 | Mar 12, 2025 |
| Mar 10, 2025 | Karin Shanahan EVP, Glob. Prod. Dev. & Supply | MOption exercise Common Stock, $0.10 par value | +14,683 | $0.00 | $0 | 22,339 | Mar 12, 2025 |
| Mar 10, 2025 | Cari Gallman EVP, Corporate Affairs | MOption exercise Common Stock, $0.10 par value | +867 | $0.00 | $0 | 6,572 | Mar 12, 2025 |
| Mar 10, 2025 | Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. | JOther Common Stock, $0.10 par value | -998 | $0.00 | $0 | 72,931 | Mar 12, 2025 |
| Mar 10, 2025 | David Elkins V EVP, Chief Financial Officer | JOther Common Stock, $0.10 par value | -1,347 | $0.00 | $0 | 209,474 | Mar 12, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Peter J Arduinidirector, ceo, president, officer
- Christopher S. BoernerChief Executive Officer
- David Elkins VEVP, Chief Financial Officer
- Cari GallmanEVP, General Counsel
- Benjamin HickeyPresident, RayzeBio Org.
- Samit HirawatEVP,Chief Med.Offr.,Drug Dev.
- Lynelle HochPresident, Cell Therapy Org.
- Phil M HolzerSVP and Controller
- Sandra LeungEVP, General Counsel
- Adam LenkowskyEVP, Chief Commercial Officer
- Cristian MassacesiEVP,Chief Med Offr,Head of Dev
- Michael R. McMullendirector
- Gregory Scott MeyersEVP, Chief Digital & Tech Off.
- Robert M PlengeEVP, Chief Research Officer
- Ahn Amanda PooleEVP, Chief People Officer
- Derica W Ricedirector
- Theodore R. Samuels IIdirector
- Karin ShanahanEVP, Glob. Prod. Dev. & Supply
- Bartie Wendy ShortEVP, Corporate Affairs
- Phyllis R Yaledirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.